Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy

Davide Vito Moretti, Giuliano Binetti, Orazio Zanetti, Giovanni Battista Frisoni IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, ItalyAbstract: Transdermal rotigotine (RTG) is a non-ergot dopamine agonist (D3>D2>D1), and is indicated for use in early and advanced Parkinson&r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Moretti DV, Binetti G, Zanetti O, Frisoni GB
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/ed132552078544d8944ec36a99bf280e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ed132552078544d8944ec36a99bf280e
record_format	dspace
spelling	oai:doaj.org-article:ed132552078544d8944ec36a99bf280e2021-12-02T06:20:28ZRotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy1178-2021https://doaj.org/article/ed132552078544d8944ec36a99bf280e2014-06-01T00:00:00Zhttp://www.dovepress.com/rotigotine-is-safe-and-efficacious-in-atypical-parkinsonism-syndromes--a17123https://doaj.org/toc/1178-2021 Davide Vito Moretti, Giuliano Binetti, Orazio Zanetti, Giovanni Battista Frisoni IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, ItalyAbstract: Transdermal rotigotine (RTG) is a non-ergot dopamine agonist (D3>D2>D1), and is indicated for use in early and advanced Parkinson’s disease (PD). RTG patch has many potential advantages due to the immediacy of onset of the therapeutic effect. Of note, intestinal absorption is not necessary and drug delivery is constant, thereby avoiding drug peaks and helping patient compliance. In turn, transdermal RTG seems a suitable candidate in the treatment of atypical Parkinsonian disorders(APS). Fifty-one subjects with a diagnosis of APS were treated with transdermal RTG. The diagnoses were: Parkinson’s disease with dementia, multiple system atrophy Parkinsonian type, multiple system atrophy cerebellar type, progressive supranuclear palsy, corticobasal degeneration, Lewy body dementia, and frontotemporal dementia with Parkinsonism. Patients were evaluated by the Unified Parkinson’s Disease Rating Scale (UPDRS; part III), Neuropsychiatric Inventory (NPI), and mini–mental state examination (MMSE) and all adverse events (AEs) were recorded. Patients treated with RTG showed an overall decrease of UPDRS III scores without increasing behavioral disturbances. Main AEs were hypotension, nausea, vomiting, drowsiness, tachycardia, and dystonia. On the whole, 15 patients were affected by AEs and seven patients suspended RTG treatment due to AEs. The results show that transdermal RTG is effective with a good tolerability profile. RTG patch could be a good therapeutic tool in patients with APS. Keywords: transdermal dopamine agonist, open label study, Parkinson plusMoretti DVBinetti GZanetti OFrisoni GBDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2014, Iss default, Pp 1003-1009 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Moretti DV Binetti G Zanetti O Frisoni GB Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy
description	Davide Vito Moretti, Giuliano Binetti, Orazio Zanetti, Giovanni Battista Frisoni IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, ItalyAbstract: Transdermal rotigotine (RTG) is a non-ergot dopamine agonist (D3>D2>D1), and is indicated for use in early and advanced Parkinson’s disease (PD). RTG patch has many potential advantages due to the immediacy of onset of the therapeutic effect. Of note, intestinal absorption is not necessary and drug delivery is constant, thereby avoiding drug peaks and helping patient compliance. In turn, transdermal RTG seems a suitable candidate in the treatment of atypical Parkinsonian disorders(APS). Fifty-one subjects with a diagnosis of APS were treated with transdermal RTG. The diagnoses were: Parkinson’s disease with dementia, multiple system atrophy Parkinsonian type, multiple system atrophy cerebellar type, progressive supranuclear palsy, corticobasal degeneration, Lewy body dementia, and frontotemporal dementia with Parkinsonism. Patients were evaluated by the Unified Parkinson’s Disease Rating Scale (UPDRS; part III), Neuropsychiatric Inventory (NPI), and mini–mental state examination (MMSE) and all adverse events (AEs) were recorded. Patients treated with RTG showed an overall decrease of UPDRS III scores without increasing behavioral disturbances. Main AEs were hypotension, nausea, vomiting, drowsiness, tachycardia, and dystonia. On the whole, 15 patients were affected by AEs and seven patients suspended RTG treatment due to AEs. The results show that transdermal RTG is effective with a good tolerability profile. RTG patch could be a good therapeutic tool in patients with APS. Keywords: transdermal dopamine agonist, open label study, Parkinson plus
format	article
author	Moretti DV Binetti G Zanetti O Frisoni GB
author_facet	Moretti DV Binetti G Zanetti O Frisoni GB
author_sort	Moretti DV
title	Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy
title_short	Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy
title_full	Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy
title_fullStr	Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy
title_full_unstemmed	Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy
title_sort	rotigotine is safe and efficacious in atypical parkinsonism syndromes induced by both a-synucleinopathy and tauopathy
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/ed132552078544d8944ec36a99bf280e
work_keys_str_mv	AT morettidv rotigotineissafeandefficaciousinatypicalparkinsonismsyndromesinducedbybothasynucleinopathyandtauopathy AT binettig rotigotineissafeandefficaciousinatypicalparkinsonismsyndromesinducedbybothasynucleinopathyandtauopathy AT zanettio rotigotineissafeandefficaciousinatypicalparkinsonismsyndromesinducedbybothasynucleinopathyandtauopathy AT frisonigb rotigotineissafeandefficaciousinatypicalparkinsonismsyndromesinducedbybothasynucleinopathyandtauopathy
_version_	1718399967607914496

Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy

Ejemplares similares